Wartapoin
Nutrition

WADA’s 2027 Prohibited List Names Peptides and Clarifies Key Drug Rules

Published Oct 30, 2026 Reads 877 By vkim

WADA’s 2027 list explicitly includes peptides among non-approved substances, while keeping semaglutide and tirzepatide under monitoring.

WADA’s 2027 Prohibited List Names Peptides and Clarifies Key Drug Rules

The list draws a clearer line around experimental peptides

WADA’s 2027 Prohibited List makes a familiar athlete calculation harder to defend: an experimental substance isn’t automatically permitted just because its name doesn’t appear on the page. The list, effective Jan. 1, explicitly includes peptides in its category for non-approved substances. The U.S. Anti-Doping Agency has warned athletes not to treat gaps in the list as loopholes. The wording matters because a prohibited category can cover substances by their characteristics and approval status, even when a particular compound isn’t named as an example.

That clarification lands in a peptide market where established medicines, experimental compounds and products with uncertain contents sit close together. The word “peptide” describes a broad class of molecules; on its own, it doesn’t tell an athlete whether a product is a medicine, whether it’s approved for human treatment, or how anti-doping rules classify it. For athletes, the distinction between a substance being unlisted and being allowed can carry consequences for a tested career. This is more significant than it looks: a search box can return no match and still leave the underlying rule unresolved.

What the peptide language means

WADA hasn’t banned every peptide. Peptides are chains of amino acids, and some are approved medicines; insulin is one example. The relevant category, S0, covers pharmacological substances that no government health authority anywhere in the world has approved for human therapeutic use, unless another prohibited category already covers them. In practice, that makes approval status central to the classification. A substance’s name, marketing claims or reputation among athletes doesn’t settle the question by itself.

Some experimental substances were prohibited before this wording change. BPC-157, for instance, was already covered by the rules on non-approved substances, while certain compounds related to growth hormone fall under other categories. The new language spells out that peptides can fall within S0. It doesn’t create a blanket ban on all peptide medicines. That distinction cuts both ways: the update signals clearer coverage for non-approved substances, while preserving the need to assess each compound under the list’s categories.

For competitors, the practical point is straightforward: a research label or an absent search result doesn’t establish that a substance is permitted. “Research use” language can describe how a seller presents a product, but it doesn’t answer how anti-doping rules apply to its contents. Athletes are responsible for what enters their bodies under anti-doping rules, and the source article notes that a coach or doctor won’t remove that responsibility. If you're working in this space, the sensible question is what the substance is and how it’s classified, not whether its name is easy to find.

Other changes and distinctions

The 2027 list names two experimental metabolic modulators, SLU-PP-332 and SLU-PP-915, as examples in its hormone and metabolic modulators category. It also adds eplerenone and finerenone as examples of diuretics and masking agents. Both drugs have legitimate medical uses, underscoring that a medication’s clinical purpose doesn’t by itself determine its status for sport. The list’s treatment of a substance is a separate question from why a patient might be prescribed it, so athletes can’t infer sporting status from a drug’s ordinary medical role.

Semaglutide and tirzepatide, active ingredients in widely used treatments for weight loss and diabetes, remain on WADA’s 2027 monitoring program. That means WADA is gathering information about their use in sport; they haven’t been added to the prohibited list. A monitoring designation and a prohibition therefore mean different things. Caffeine is another monitored substance, and it isn’t prohibited. Those distinctions are easy to blur when several categories appear together in a single list, but they matter to anyone interpreting what an athlete may take.

WADA also clarified its cannabis language. Psychoactive cannabinoids related to THC, including some synthetic and semi-synthetic forms, are prohibited in competition. CBD itself isn’t prohibited, but a CBD product with undeclared THC can still lead to a failed drug test. The label on a product may not fully describe what’s in it, which makes the gap between a permitted ingredient and an undisclosed one a practical concern. (And this is the part most people overlook.)

Research claims don’t settle the question

There’s a case for researching performance-related substances: research can lead to useful discoveries. But early promise, including results from animal studies, doesn’t establish safety or effectiveness in humans. That gap is especially relevant when compounds are described in terms of potential benefits before there’s enough evidence to answer basic questions about their effects in people. An encouraging claim is a starting point for investigation, not proof that a substance is safe or useful for an athlete.

Anecdotal claims can still be persuasive, particularly when athletes believe detection is unlikely or assume that a product sold openly must be acceptable. Neither assumption resolves the questions the list raises. What’s in the product may be uncertain, and a substance’s status doesn’t depend on whether a competitor expects to be tested. The numbers here are underwhelming in one sense: a product’s promise can be much easier to find than reliable answers about its contents and effects.

What the update means for athletes

That leaves athletes weighing more than whether a substance appears by name. They need to check its actual status and account for the risks of products with uncertain ingredients. WADA’s updated wording puts the focus on approval status and substance categories, while the monitoring program shows that being watched and being prohibited remain distinct. For anyone whose competitive eligibility matters, checking before taking an experimental peptide is the practical takeaway.

There’s no shortcut in a name search. Athletes and the people advising them have to understand which category applies, whether a substance has approval for human therapeutic use, and whether the product’s contents are clear. That can be an inconvenient standard when a compound is marketed with confident claims or described as experimental research. Still, the list makes the basic point plain: uncertainty about a substance isn’t evidence that it’s allowed.

And yet. The update doesn’t resolve every question an athlete may have about a specific product, especially where ingredients are uncertain or a substance falls under another category. It does make the governing principle harder to miss: absence from a list of named examples isn’t the same as permission. For competitors, that distinction deserves attention before a substance is taken, not after a test raises the issue.

Source: vkim · www.muscleandfitness.com

Discussion

Sign in to join the discussion.